NCT01405599已完成1 期
Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ulimorelin in Subjects With Mild, Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects
Norgine1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Cmax of ulimorelin
研究概览
简要总结
Evaluation of the effect of hepatic impairment on the pharmacokinetics of ulimorelin after a single intravenous (IV) dose in order to identify potential patients at risks in terms of severity of hepatic dysfunction and to determine whether their dosage should be adjusted.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Main Criteria for Inclusion All Subjects:
- •Adult male or female subjects age 18 to 75 years (both inclusive)
- •Able to understand and willing to sign an informed consent form (ICF) and able to comply with the study restrictions
- •Female subjects must be postmenopausal (for at least 1 year and confirmed by serum follicle-stimulating hormone (FSH) at screening), surgically sterile, practicing true abstinence and/or must be using adequate contraception for the duration of the study (e.g. contraceptive implants, injectables, oral contraceptives, and intra-uterine device and/or barrier methods (condom/occlusive cap with spermicidal foam/gel/film/cream/suppository))
- •Females of childbearing potential must have a negative pregnancy test at screening and Day -1
- •Weight ≥ 50 kg and ≤ 200 kg
- •Body mass index (BMI) ≤ 40.0 kg/m2, where BMI (kg/m2) = Body weight (kg)/Height2 (m2) Inclusion Criteria Hepatic Impairment Subjects (in addition to the criteria for all subjects):
- •Documented mild, moderate or severe hepatic impairment defined as either Child-Pugh A, B or C at screening
- •Stable hepatic impairment, defined as no clinically significant change in disease status within the last 30 days before screening, as documented by the subject's recent medical history (e.g., no worsening of clinical signs of hepatic impairment and no worsening of total bilirubin or prothrombin time by more than 50%)
- •Must be on a stable dose of medication and/or treatment regimen at least 2 weeks before dosing of study medication
- •Subjects with a history of substance abuse may be enrolled provided that they have not abused drugs or alcohol for at least 6 months preceding the study Inclusion Criteria for Healthy Subjects (in addition to criteria for all subjects):
- •Subjects with normal hepatic function, and liver parameters within normal range unless approved by the Sponsor's Medical Representative
- •Subjects not using prescription drugs or non-prescription drugs, including over-the-counter medication, non-routine vitamins and herbal products within 3 weeks prior to dosing of investigational product [use of oral contraceptives, diuretics, noncardioselective beta-blockers, topically applied medication (eye-/nose-drops and creams) and occasional use of metaclopramide, ibuprofen and paracetamol is permitted]. Use of any other medication has to be discussed and agreed before inclusion of the subject with the Medical Monitor and the Sponsor's medical representative
排除标准
- •Criteria for Exclusion All Subjects:
- •Known or suspected allergy to the trial product or related products
- •History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction
- •Participation in another investigational drug trial within 30 days prior to dosing (or 5 times the half life of the drug if longer)
- •Acute illness within 14 days prior to dosing unless mild in severity and approved by the Investigator and Sponsor's medical representative
- •History of drug abuse or positive urine drug screen (if not due to concomitant medication) at Screening and/or Day -1
- •Ingestion of alcohol and caffeine within 24 hours prior to dosing and for the duration of the study
- •Donation of more than 450mL of blood / blood products in the 30 days prior to dosing, and/or blood donation in the 30 days prior to dosing
- •Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies or HIV-1 antigen according to locally used diagnostic testing
- •Creatinine clearance <50mL/minute, estimated using serum creatinine with the formula [(140 - age in years) × weight in kg]/[(72 × serum creatinine in mg/dL) × 0.85 for female subjects]
- •Consumption of Seville oranges, grapefruit or grapefruit juice, star fruit and exotic fruits from 7 days prior to first dose of study medication and for entire duration of the study
- •Clinically significant abnormal haematology, biochemistry, coagulation or urinalysis screening tests, as judged by the Investigator other than the abnormal values expected considering the underlying disease
- •Subject with any disease or condition which the Investigator feels would interfere with the trial outcome or compliance except for conditions associated with hepatic impairment in the group of subjects with compromised hepatic function
- •Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and /or diastolic blood pressure ≥ 105 mmHg)
- •Use of prescription or over-the-counter medication that is extensively bound to α1-acid glycoprotein (AAG) which the Investigator or Sponsor feels would interfere with the trial outcome
- •History of cancer (judged not to be in full remission) or presence of cancer (except basal cell skin cancer or squamous cell skin cancer) as judged by the Investigator
- •Subject who has undergone liver transplantation
- •Not able or willing to refrain from smoking during the inpatient period
- •Any condition that would make the subject unsuitable for clinical trial participation as judged by the Investigator
- •Exclusion Criteria Hepatic Impairment Subjects (in addition to criteria for all subjects):
- •Any medical or surgical conditions, excluding underlying liver disease, which may significantly interfere with the pharmacokinetics of the study drug
- •Fluctuating or rapidly deteriorating hepatic function
- •Exclusion Criteria for Healthy Subjects (in addition to criteria for all subjects):
- •Subjects with clinically significant illness as judged by the Investigator
- •Exposure to more than three new chemical entities within 12 months prior to the first dosing day
- •Known acute hepatitis with viral, alcoholic, toxic or autoimmunological aetiology within the last 6 months. Positive result to the screening test for Hepatitis B antigen or Hepatitis C antibodies according to locally used diagnostic testing
- •Strenuous exercise within 48 hours prior to dosing and for the duration of the study
研究组 & 干预措施
Control
Experimental
Healthy subjects
干预措施: Ulimorelin (Drug)
Severe hepatic impairment
Experimental
CTP class C
干预措施: Ulimorelin (Drug)
Moderate hepatic impairment
Experimental
CTP class B
干预措施: Ulimorelin (Drug)
Mild hepatic impairment
Experimental
CTP class A
干预措施: Ulimorelin (Drug)
结局指标
主要结局
Cmax of ulimorelin
时间窗: 15, 30, 45, 60, 75, 90 mins, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 h post-infusion
To evaluate the pharmacokinetics of ulimorelin in subjects with mild, moderate and severe hepatic impairment compared with subjects who have normal hepatic function following a single dose administration of ulimorelin
AUC of ulimorelin
时间窗: 15, 30, 45, 60, 75, 90 mins, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 h post-infusion
To evaluate the pharmacokinetics of ulimorelin in subjects with mild, moderate and severe hepatic impairment compared with subjects who have normal hepatic function following a single dose administration of ulimorelin
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)LeiomyomaNCT03092999Bayer36
已完成
1 期
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupPharmacokinetics of MDV3100Healthy SubjectsKidney DiseasesNCT01901133Astellas Pharma Europe B.V.33
已完成
1 期
Pharmacokinetics of Mitiperstat in Participants With Hepatic ImpairmentHepatic ImpairmentNCT05751759AstraZeneca31
已完成
1 期
Pharmacokinetics of ZSP1273 in Participants With Hepatic ImpairmentHepatic ImpairmentPharmacokineticsNCT05856513Guangdong Raynovent Biotech Co., Ltd24
已完成
1 期
Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic ImpairmentHepatic ImpairmentNCT06161259Guangdong Raynovent Biotech Co., Ltd24